Valvular & structural heart disease
Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial
Primary result · All-cause mortality, stroke or MIResult — go to the resultHazard ratio 1.0 95% CI 0.7–1.3Authors' conclusion
In patients with severe AS and lower surgical risk randomized to TAVI or SAVR, the risk of major clinical outcomes was not different 10 years after treatment. The risk of severe bioprosthesis SVD was lower after TAVR compared with SAVR, while the risk of BVF was similar.
Study context
- Population
- Patients with severe AS at lower surgical risk
- Participants
- 280 patients
- Comparison
- Transcatheter aortic valve implantation (TAVI) vs surgical aortic valve replacement (SAVR)
- TAVIn = 145
- SAVRn = 135reference
- Primary endpoint
- Composite of:
- All-cause mortality
- Stroke
- MI
- Follow-up
- 10 years
Methodological details10-year follow-up
- 10-year follow-up
Primary result
All-cause mortality, stroke or MI
Hazard ratio
1.0
95% CI 0.7–1.3
P = 0.9
By group
TAVIvs SAVR
HR 1.0 (95% CI 0.7–1.3); P = 0.9
As reported in the abstract
Further findings
| Outcome | TAVI | SAVR | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| Severe SVD · 10 years | 1.5% | 10.0% | 0.2 (0.04–0.7) | P = 0.02 | |
| Bioprosthetic valve failure · 10 years | 9.7% | 13.8% | 0.7 (0.4–1.5) | P = 0.4 | |
| 0.050.21520Hazard ratio (log scale) |
Severe NSVD (cumulative incidence) · 10 years
P < 0.001
Safety
Endocarditis (cumulative incidence) · 10 years
P = 1.0
Clinical valve thrombosis · 10 years
- No patients had clinical valve thrombosis
Original publication
Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J. Published 7 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →